As of Nov 19, 2026, 1 of 1 active firms rate CUE a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CUE EPS & revenue forecast
EPS · NEXT QUARTER
$-1.76
Range $-2.83 – $-0.98 · 3 analysts · -686% YoY
Next period, 3 analysts expect Cue Biopharma to earn $-1.76 a share (range $-2.83 – $-0.98), versus $0.30 a year earlier. Full-year consensus is $-25.01, growing to $-7.44 the year after.
REVENUE · NEXT QUARTER
$1.0M
Range $0 – $2.0M · 3 analysts · -95% YoY
Revenue is expected to reach $1.0M (range $0 – $2.0M), -95.4% year-over-year. Full-year consensus is $15.6M, rising to $8.7M next year.
Top analysts covering Cue Biopharma
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CUE.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$83.00+1654.8% to target
Overall win rate
49%
+ Follow
#2
Reni J. Benjamin
JMP Securities · Rank #489
Buy
$2.00-57.7% to target
Overall win rate
29%
+ Follow
#3
DP
Dev Prasad
Lucid Capital
Buy
$4.00-15.4% to target
Coverage
—
+ Follow
#4
DP
Dev Prasad
LUCID CAPITAL MARKETS
Buy
$4.00-15.4% to target
Coverage
—
+ Follow
CUE stock forecast FAQ
What is CUE's average 12-month price target?+
The 1 active firms with a live target average $83.00 for Cue Biopharma over the next 12 months, ranging from a $83.00 high to a $83.00 low, as of Nov 19, 2026.
Is CUE stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover CUE?+
1 active firms have a recognized rating on Cue Biopharma as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CUE?+
Among analysts who currently cover CUE, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $83.00 target.
What is Cue Biopharma's projected EPS for next quarter?+
The consensus estimate is $-1.76 per share (range $-2.83 – $-0.98) across 3 analysts. Full-year EPS is projected at $-25.01, rising to $-7.44 the following year.
How much revenue is Cue Biopharma expected to report next quarter?+
Consensus revenue is $1.0M (range $0 – $2.0M). Full-year revenue is projected at $15.6M, growing to $8.7M next year.
Have analysts been upgrading or downgrading CUE lately?+
As of Nov 19, 2026, 1 of 1 active firms rate CUE a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CUE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.